Gamma Secretase Inhibitors in Cancer
DOI:
https://doi.org/10.22376/ijtos.2025.3.1.1-7Keywords:
GSIs, Notch signaling, Cancer stem-like cells, EMT, Immune responses in cancer, Combinatorial cancer therapyAbstract
Gamma secretase inhibitors (GSIs), for Alzheimer's disease treatment, have been repurposed as anticancer agents because they inhibit receptor cleavage. Preclinical studies suggested that GSIs effectively promote the differentiation and apoptosis of cancer stem-like cells while obstructing epithelial-to-mesenchymal transition and increasing sensitivity to conventional chemotherapy and radiotherapies. However, their clinical application remains limited, as GSIs have shown minimal efficacy in the majority of solid tumors, with significant exceptions including central nervous system malignancies and desmoid tumors. It highlights several unresolved questions, including their overall impact on anticancer immune responses and whether targeting tumor-intrinsic compensatory pathways would be necessary for achieving optimal results. Advancing our understanding of GSI mechanisms is critical for effectively integrating these inhibitors into combination therapies and addressing Notch-dependent cancers. This review aims to provide a comprehensive overview of GSI mechanisms, analyze their clinical effects thus far, and propose future research directions. It emphasizes the importance of evaluating GSIs' effects on immune responses in cancer patients and overcoming tumor-intrinsic resistance to unlock their full therapeutic potential, paving the way for more effective combinatorial strategies in oncology.
References
McCaw TR, Inga E, Chen H, Jaskula‐Sztul R, Dudeja V, Bibb JA, Ren B, Rose JB. Gamma secretase inhibitors in cancer: a current perspective on clinical performance. The oncologist. 2021 Apr 1;26(4):e608-21.
You WK, Schuetz TJ, Lee SH. Targeting the DLL/Notch signaling pathway in cancer: challenges and advances in clinical development. Molecular cancer therapeutics. 2023 Jan 3;22(1):3-11.
Ip WH, Dobner T. Cell transformation by the adenovirus oncogenes E1 and E4. FEBS letters. 2020 Jun;594(12):1848-60.
Zhang Z, Lu YX, Liu F, Sang L, Shi C, Xie S, Bian W, Yang JC, Yang Z, Qu L, Chen SY. lncRNA BREA2 promotes metastasis by disrupting the WWP2-mediated ubiquitination of Notch1. Proceedings of the National Academy of Sciences. 2023 Feb 21;120(8):e2206694120.
Meisel CT, Porcheri C, Mitsiadis TA. Cancer stem cells, quo vadis? The Notch signaling pathway in tumor initiation and progression. Cells. 2020 Aug 11;9(8):1879.
Li X, Yan X, Wang Y, Kaur B, Han H, Yu J. The Notch signaling pathway: a potential target for cancer immunotherapy. Journal of hematology & oncology. 2023 May 2;16(1):45.
McCaw TR, Inga E, Chen H, Jaskula‐Sztul R, Dudeja V, Bibb JA, Ren B, Rose JB. Gamma secretase inhibitors in cancer: a current perspective on clinical performance. The oncologist. 2021 Apr 1;26(4):e608-21.
López‐Nieva P, González‐Sánchez L, Cobos‐Fernández MÁ, Córdoba R, Santos J, Fernández‐Piqueras J. More insights on the use of γ‐secretase inhibitors in cancer treatment. The Oncologist. 2021 Feb 1;26(2):e298-305.
Motais B, Charvátová S, Hrdinka M, Hájek R, Bago JR. Anti-BCMA-CAR NK cells expressing soluble TRAIL: promising therapeutic approach for multiple myeloma in combination with bortezomib and γ-secretase inhibitors. Blood. 2022 Nov 15;140(Supplement 1):12683-4.
Duranti E, Cordani N, Villa C. Edaravone: A Novel Possible Drug for Cancer Treatment?. International Journal of Molecular Sciences. 2024 Jan 29;25(3):1633.
Ma K, Li S, Huo X, Guo M, Du X, Li C, Liu X, Lv J, Chen Z. Exploring the mechanism of cisplatin resistance by transcriptome sequencing and reversing the chemoresistance by autophagy inhibition in small cell lung cancer. Biochemical and Biophysical Research Communications. 2020 Dec 10;533(3):474-80.
Sun J, Dong M, Xiang X, Zhang S, Wen D. Notch signaling and targeted therapy in non-small cell lung cancer. Cancer Letters. 2024 Jan 30:216647.
Tendler S, Kanter L, Lewensohn R, Ortiz-Villalón C, Viktorsson K, De Petris L. The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy. PLoS One. 2020 Oct 26;15(10):e0240973.
Feng M, Santhanam RK, Xing H, Zhou M, Jia H. Inhibition of γ-secretase/Notch pathway as a potential therapy for reversing cancer drug resistance. Biochemical Pharmacology. 2023 Dec 20:115991.
Riudavets M, Sullivan I, Abdayem P, Planchard D. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO open. 2021 Oct 1;6(5):100260.
Riess JW, Reckamp KL, Frankel P, Longmate J, Kelly KA, Gandara DR, Weipert CM, Raymond VM, Keer HN, Mack PC, Newman EM. Erlotinib and analepsis lactate focused on EGFR exon 20 insertions non-small cell lung cancer (NSCLC): a California Cancer Consortium Phase I/II Trial (NCI 9878). Clinical lung cancer. 2021 Nov 1;22(6):541-8.
Moore G, Annett S, McClements L, Robson T. Top notch targeting strategies in cancer: a detailed overview of recent insights and current perspectives. Cells. 2020 Jun 20;9(6):1503.
Sardesai S, Badawi M, Mrozek E, Morgan E, Phelps M, Stephens J, Wei L, Kassem M, Ling Y, Lustberg M, Stover D. A phase I study of an oral selective gamma-secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple-negative breast cancer. Investigational new drugs. 2020 Oct;38:1400-10.
Ghanbari-Movahed M, Ghanbari-Movahed Z, Momtaz S, Kilpatrick KL, Farzaei MH, Bishayee A. Unlocking the secrets of cancer stem cells with γ-secretase inhibitors: A novel anticancer strategy. Molecules. 2021 Feb 12;26(4):972.
Ferrarotto R, Metcalf R, Rodriguez CP, Muzaffar J, Even C, Perez CA, Van Herpen CM, Oliva M, Xia B, Bowles DW, Popovtzer A. Results of ACCURACY: A phase 2 trial of AL101, a selective gamma-secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut).
Yokose T, Kitano M, Matsusaka Y, Masugi Y, Shinoda M, Yagi H, Abe Y, Oshima G, Hori S, Endo Y, Toyama K. Usefulness of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenocarcinoma. Cancer medicine. 2020 Jun;9(12):4059-68.
Kipper FC, Kieran MW, Thomas A, Panigrahy D. Notch signaling in malignant gliomas: Supporting tumor growth and the vascular environment. Cancer and Metastasis Reviews. 2022 Sep;41(3):737-47.
Feng M, Santhanam RK, Xing H, Zhou M, Jia H. Inhibition of γ-secretase/Notch pathway as a potential therapy for reversing cancer drug resistance. Biochemical Pharmacology. 2023 Dec 20:115991.
Lato MW, Przysucha A, Grosman S, Zawitkowska J, Lejman M. The new therapeutic strategies in pediatric T-cell acute lymphoblastic leukemia. International Journal of Molecular Sciences. 2021 Apr 26;22(9):4502.
Adachi T, Miyashita S, Yamashita M, Shimoda M, Okonechnikov K, Chavez L, Kool M, Pfister SM, Inoue T, Kawauchi D, Hoshino M. Notch signaling between cerebellar granule cell progenitors. eneuro. 2021 May 1;8(3).
Mattei V, Santilli F, Martellucci S, Delle Monache S, Fabrizi J, Colapietro A, Angelucci A, Festuccia C. The importance of tumor stem cells in glioblastoma resistance to therapy. International Journal of Molecular Sciences. 2021 Apr 8;22(8):3863.
Mijailovic I, Nikolic N, Djinic A, Carkic J, Milinkovic I, Peric M, Jankovic S, Milasin J, Aleksic Z. The down‐regulation of Notch 1 signaling contributes to the severity of bone loss in aggressive periodontitis. Journal of Periodontology. 2020 Apr;91(4):554-61.
Serrano D, Gandini S, Thomas P, Crew KD, Kumar NB, Vornik LA, Lee JJ, Veronesi P, Viale G, Guerrieri-Gonzaga A, Lazzeroni M. Efficacy of alternative dose regimens of exemestane in postmenopausal women with stage 0 to II estrogen receptor-positive breast cancer: a randomized clinical trial. JAMA oncology. 2023 May 1;9(5):664-72.
Lee JS, Yost SE, Yuan Y. Neoadjuvant treatment for triple-negative breast cancer: recent progresses and challenges. Cancers. 2020 May 29;12(6):1404.
Arrieta O, Barrón F, Ramírez-Tirado LA, Zatarain-Barrón ZL, Cardona AF, Díaz-García D, Ramos MY, Mota-Vega B, Carmona A, Álvarez MP, Bautista Y. Efficacy and safety of pembrolizumab plus docetaxel vs docetaxel alone in patients with previously treated advanced non–small cell lung cancer: The PROLUNG phase 2 randomized clinical trial. JAMA oncology. 2020 Jun 1;6(6):856-64.
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomized, placebo-controlled, phase 3 study. The Lancet Oncology. 2020 Apr 1;21(4):519-30.
Glibo M, Serman A, Karin-Kujundzic V, Vlatkovic IB, Miskovic B, Vranic S, Serman L. The role of glycogen synthase kinase 3 (GSK3) in cancer with emphasis on ovarian cancer development and progression: A comprehensive review. Bosnian journal of basic medical sciences. 2021 Feb;21(1):5.
Clara JA, Monge C, Yang Y, Takebe N. Targeting signaling pathways and the immune microenvironment of cancer stem cells—a clinical update. Nature Reviews Clinical Oncology. 2020 Apr;17(4):204-32.
Ma H, Tian T, Cui Z. Targeting ovarian cancer stem cells: a new way out. Stem Cell Research & Therapy. 2023 Feb 14;14(1):28.
Goenka A, Khan F, Verma B, Sinha P, Dmello CC, Jogalekar MP, Gangadaran P, Ahn BC. Tumor microenvironment signaling and therapeutics in cancer progression. Cancer Communications. 2023 May;43(5):525-61.
Sabol HM, Ashby C, Adhikari M, Anloague A, Kaur J, Khan S, Choudhury SR, Schinke C, Palmieri M, Barnes CL, Ambrogini E. A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma. Haematologica. 2024 Feb 22;109(8):2606.
Brisset M, Mehlen P, Meurette O, Hollande F. Notch receptor/ligand diversity: contribution to colorectal cancer stem cell heterogeneity. Frontiers in Cell and Developmental Biology. 2023 Oct 4;11:1231416.
Ghosh A, Mitra AK. Metastasis and cancer-associated fibroblasts: taking it up as a NOTCH. Frontiers in Cell and Developmental Biology. 2024 Jan 10;11:1277076.
Hubbard JM, Yin J, Schenk EL, Qin R, Reid JM, Strand C, Fiskum J, Menefee M, Lin G, Doyle LA, Ivy P. Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. Investigational new drugs. 2022 Feb 1:1-9.
Tufail M, Wu C. Targeting the IGF-1R in prostate and colorectal cancer: reasons behind trial failure and future directions. Therapeutic Delivery. 2022 Mar 1;13(3):167-86.
Borah AK, Singh CS. 13 The Emerging Role of the. Handbook of Proteases in Cancer: Therapeutic Aspects. 2024 Dec 17:162.
Gao J, Fan L, Zhao L, Su Y. The interaction of Notch and Wnt signaling pathways in vertebrate regeneration. Cell Regeneration. 2021 Dec;10:1-7.
Kasper B, Baldini EH, Bonvalot S, Callegaro D, Cardona K, Colombo C, Corradini N, Crago AM, Dei Tos AP, Dileo P, Elnekave E. Current Management of Desmoid Tumors: A Review. JAMA oncology. 2024.
Mangla A, Agarwal N, Schwartz G. Desmoid tumors: current perspective and treatment. Current Treatment Options in Oncology. 2024 Feb;25(2):161-75.
Keam SJ. Nirogacestat: First Approval. Drugs. 2024 Mar;84(3):355-61.
Published
How to Cite
Issue
Section
Copyright (c) 2025 Dr. V. Aruna, Dr. Anand Mohan Jha, Dr Riffat A Fatima, Dr. Abikesh Prasada Kumar Mahapatra
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
